UroGen Pharma Ltd.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $70.8M | $-17.1M | $105.4M |
| Jun 2022 | $71.2M | $-40.9M | $80.7M |
| Sep 2022 | $71.9M | $-63.3M | $28.7M |
| Dec 2022 | $97.5M | $-89.4M | $55.4M |
| Mar 2023 | $97.9M | $-116.6M | $36.5M |
| Jun 2023 | $98.3M | $-138.4M | $20.1M |
| Sep 2023 | $98.5M | $-42.0M | $119.3M |
| Dec 2023 | $98.6M | $-65.2M | $95.0M |
| Mar 2024 | $97.6M | $-40.1M | $131.4M |
| Jun 2024 | $97.8M | $30.3M | $220.0M |
| Sep 2024 | $121.7M | $25.5M | $124.9M |
| Dec 2024 | $121.7M | $-8.8M | $172.0M |
| Mar 2025 | $122.1M | $-46.5M | $104.0M |
| Jun 2025 | $122.5M | $-93.4M | $92.9M |
| Sep 2025 | $122.1M | $-115.4M | $90.0M |
| Dec 2025 | $122.2M | $-105.5M | $110.7M |
| Mar 2026 | $189.5M | $-124.3M | $110.0M |
| Jun 2026 | $188.7M | $-132.4M | $79.1M |